Intravesical Capsaicin Versus Resiniferatoxin for the Treatment of Detrusor Hyperreflexia in Spinal Cord Injured Patients:: A Double-Blind, Randomized, Controlled Study
- 1 January 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 171 (1) , 251-255
- https://doi.org/10.1097/01.ju.0000100385.93801.d4
Abstract
Chemical defunctionalization of C-fiber bladder afferents with intravesical vanilloids such as capsaicin (CAP) or resiniferatoxin (RTX) improves detrusor hyperreflexia in humans and animals. The little existing data comparing the efficacy and tolerance of these 2 vanilloid agents seem to favor RTX in 10% alcohol over CAP, which is usually diluted in 30% alcohol. We compared the efficacy and tolerability of the 2 vanilloid agonists in what to our knowledge is the first randomized, controlled study comparing nonalcohol CAP vs RTX in 10% alcohol in neurogenic patients with detrusor hyperreflexia. This single center, randomized, double-blind, parallel groups study included 39 spinal cord injured adults with detrusor hyperreflexia. On day 0 patients were randomized to receive 1, 100 ml intravesical instillation of 100 nMol/l RTX diluted in 10% ethanol or 1 mmol/l CAP diluted in glucidic solvent. Efficacy (voiding chart and cystomanometry) and tolerability were evaluated during a 3-month followup. On day 30 clinical and urodynamical improvement was found in 78% and 83% of patients with CAP vs 80% and 60% with RTX, respectively, without a significant difference between the 2 treated groups. The benefit remained in two-thirds of the 2 groups on day 90. There were no significant differences in regard to the incidence, nature or duration of side effects in CAP vs RTX treated patients. Our results strongly argue for the importance of accounting for the role of vanilloid solute when interpreting the efficacy and tolerance of vesical vanilloid instillation in detrusor hyperreflexia cases. They suggest that a glucidic solute is a valuable solvent for vanilloid instillation.Keywords
This publication has 20 references indexed in Scilit:
- Capsaicin and neurogenic detrusor hyperreflexia: A double-blind placebo-controlled study in 20 patients with spinal cord lesionsNeurourology and Urodynamics, 1998
- Intravesical Resiniferatoxin for the Treatment of Detrusor Hyperreflexia Refractory to Capsaicin in Patients with Chronic Spinal Cord DiseasesScandinavian Journal of Urology and Nephrology, 1998
- INTRAVESICAL CAPSAICIN AS A TREATMENT FOR REFRACTORY DETRUSOR HYPERREFLEXIA: A DUAL CENTER STUDY WITH LONG-TERM FOLLOWUPJournal of Urology, 1997
- Suppression of bladder hyperreflexia by intravesical resiniferatoxinThe Lancet, 1997
- Desensitization of Bladder Sensory Fibers by Intravesical Capsaicin has Long Lasting Clinical and Urodynamic Effects in Patients With Hyperactive or Hypersensitive Bladder DysfunctionJournal of Urology, 1997
- Vanilloid receptors: new insights enhance potential as a therapeutic targetPain, 1996
- Mechanisms underlying the recovery of lower urinary tract function following spinal cord injurySpinal Cord, 1995
- Intravesical capsaicin for treatment of detrusor hyperreflexia.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Neuropharmacological mechanisms of capsaicin and related substancesBiochemical Pharmacology, 1992
- Intravesical capsaicin for neurogenic bladder dysfunctionThe Lancet, 1992